Armata Pharmaceuticals, Inc.

AMEX:ARMP

Biotechnology

Healthcare
$3.17 -0.28%

-$0.02 today

Market cap
$117.90M
Beta
1.22
P/E (TTM)
-0.9
EPS (TTM)
-$7.74
52W Low $1.81High $16.34

Volume 0.09M

Average 0.07M

ARMP Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Armata Pharmaceuticals, Inc.AMEX: ARMP

Short-term Debt · Q1 FY2026 · quarter ended Mar 2026

Short-term debt remains negative

Q1 FY2026 short-term debt was $0, compared with $102.78M a year earlier.

Context

  • Short-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, down 117.8 pp from a year earlier.
  • Short-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether short-term debt keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
Year agoMar 2025
$102.78M-100.0% since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Short-term Debt vs competitors

How ARMP compares with its peers on the latest reported figures

  • ARMP's Mar 2026 short-term debt of $0 is the highest of the 2 companies compared; the peer median is $0.
  • Its year-over-year change of -100.0% is the highest of 2, against a peer median of -100.0%.
  • Short-term debt amounts to 0.0% of total assets for ARMP, versus a peer median of 0.0%.
ARMP Competitors Peer median
Short-term Debt for ARMP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ARMPArmata Pharmaceuticals, Inc.Mar 2026$0 -100.0%—0.0%
SPROSpero Therapeutics, Inc.Mar 2026$0 -100.0%+5.0%0.0%
Peer median (excluding ARMP) $0-100.0%+5.0%0.0%

Competitors are the stored peer set for ARMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents10.29M14.85M13.52M9.29M8.69M
Short-term Investments00000
Net Receivables2.99M1.94M3.36M744K472K
Inventory00000
Other Current Assets1.72M10.26M2.27M1.27M1.51M
Total Current Assets15M27.05M19.15M11.31M10.67M
Property, Plant & Equipment (Net)38.07M46.65M57.28M54.93M46.11M
Goodwill3.49M3.49M3.49M3.49M3.49M
Intangible Assets10.26M10.26M10.26M10.26M10.26M
Long-term Investments05.96M05.48M5.39M
Tax Assets012.04M000
Other Non-current Assets2.96M2.43M8.19M975K973K
Total Non-current Assets54.77M80.83M79.21M75.13M66.21M
Total Assets69.77M107.88M98.36M86.44M76.88M
Account Payables1.14M6.03M1.59M766K921K
Short-term Debt1.51M17.01M9.48M38.95M0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities001.29M529K1.27M
Total Current Liabilities4.81M24.87M16.46M48.25M8.95M
Long-term Debt0082.31M55.44M256.92M
Deferred Tax Liabilities3.08M15.12M3.08M3.08M3.08M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities39.56M46.92M113.97M86.21M286.53M
Total Liabilities44.37M71.8M130.43M134.46M295.48M
Common Stock271K361K361K362K364K
Retained Earnings(202.86M)(239.77M)(308.82M)(327.74M)(501.53M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity25.4M36.08M(32.07M)(48.02M)(218.6M)
Total Debt37.99M48.82M120.37M126.52M288.02M
Net Debt27.7M33.96M106.85M117.22M279.33M

Armata Pharmaceuticals, Inc.

AMEX:ARMP

Intrinsic Alpha fair value

Locked

Current Price

$3.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.